China SXT Pharmaceuticals Files 6-K with Purchase Agreement
Ticker: SXTC · Form: 6-K · Filed: 2026-04-09T09:00:31-04:00
Sentiment: neutral
Topics: foreign-issuer, securities-purchase-agreement, legal-opinion
TL;DR
SXT filed a 6-K on 4/9/26 detailing a securities purchase agreement from 4/7/26.
AI Summary
China SXT Pharmaceuticals, Inc. filed a Form 6-K on April 9, 2026, reporting its status as a foreign issuer. The filing includes a Securities Purchase Agreement dated April 7, 2026, and an opinion from Appleby. The company's mailing and business address are both listed as 178 Taidong Road North, Taizhou, China.
Why It Matters
This filing indicates ongoing corporate activities and potential transactions for China SXT Pharmaceuticals, Inc., which could impact its future operations and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine report of a foreign issuer and does not contain significant negative news or financial distress indicators.
Key Players & Entities
- China SXT Pharmaceuticals, Inc. (company) — Filer
- Appleby (company) — Legal counsel providing an opinion
- April 9, 2026 (date) — Filing Date
- April 7, 2026 (date) — Date of Securities Purchase Agreement
FAQ
What is the purpose of the Form 6-K filing by China SXT Pharmaceuticals, Inc.?
The Form 6-K is a report of a foreign issuer, filed on April 9, 2026, to provide updates and relevant documents to the SEC.
What key documents are included in this 6-K filing?
The filing includes the main report, an opinion from Appleby, and a Form of Securities Purchase Agreement dated April 7, 2026.
When was the Securities Purchase Agreement dated?
The Form of Securities Purchase Agreement is dated as of April 7, 2026.
What is the business address of China SXT Pharmaceuticals, Inc.?
The business address is 178 Taidong Road North, Taizhou, China.
What is the CIK number for China SXT Pharmaceuticals, Inc.?
The CIK number for China SXT Pharmaceuticals, Inc. is 0001723980.
From the Filing
EDGAR Filing Documents for 0001213900-26-041765 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001213900-26-041765 Filing Date 2026-04-09 Accepted 2026-04-09 09:00:31 Documents 4 Period of Report 2026-04-09 Document Format Files Seq Description Document Type Size 1 REPORT OF FOREIGN PRIVATE ISSUER ea0285552-6k_chinasxt.htm 6-K 14726 2 OPINION OF APPLEBY ea028555201ex5-1.htm EX-5.1 61517 3 FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF APRIL 7, 2026 ea028555201ex10-1.htm EX-10.1 182535 4 GRAPHIC ea028555202_ex5-1img1.jpg GRAPHIC 4159 Complete submission text file 0001213900-26-041765.txt 265766 Mailing Address 178 TAIDONG ROAD NORTH TAIZHOU China Business Address 178 TAIDONG ROAD NORTH TAIZHOU China 8652386298290 China SXT Pharmaceuticals, Inc. (Filer) CIK : 0001723980 (see all company filings) EIN. : 000000000 | State of Incorp.: D8 | Fiscal Year End: 0331 Type: 6-K | Act: 34 | File No.: 001-38773 | Film No.: 26849959 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)